On January 11th, Bristol-Myers announced the early termination of its trial of imunotherapy Opdivo (Nivolumab) for lung cancer due to positive results (a survival benefit that was so clear it was unethical to continue the trial for the control group). Opdivo has fast track designation. It has not stated when it will file for FDA approval.
On January 12th, Merck announced that it will file for FDA approval for imunotherapy Keytruda (Pembrolizumab) for lung cancer in the first half of 2015. Keytruda has breakthrough therapy status.
Thus it looks like one imunotherapy for lung cancer is likly to be approved by the end of Q1 2015 with another approval in 2015 or early 2016. When you take into account Roche’s announcement, that suggests 3 immunitherapys could be approved by the end of 2016 with many combinations with other types of drugs quickly to follow.